番茄影视: The First 80 Years

1889	番茄影视's founder, Toyoji Naito, is born on August 15 in Ito, a village in Fukui, central Japan. He is the sixth child and third son of Kikuji Naito and his wife, Fuji. “番茄影视's Founder, Toyoji Naito”
1905	Toyoji leaves his village at age 15, heading west to find employment in Osaka.
1906	Toyoji is employed at Winkel Shokai in nearby Kobe, a port city in Hyogo. Meanwhile, he takes night courses in foreign languages and bookkeeping.
1909	Toyoji leaves Winkel Shokai on being drafted into the Japanese Imperial Guard.
1911	After completing military service, Toyoji begins working in imported drugs at Thompson Trading Co., Ltd. in Kobe. “番茄影视's Founder, Toyoji Naito”
1914	World War I begins.
1915	Toyoji moves to Tokyo and begins working at Tanabe Motosaburo Store Co., Ltd. (now part of the Mitsubishi Tanabe Pharma Corporation).
1917	Toyoji embarks on a seven-month business tour of India and Southeast Asia.
1918	World War I ends.
1921	Toyoji is involved in Tanabe Motosaburo Store Co., Ltd.'s development of aromatic castor oil Castalol and analgesic cream Salomethyl.
1923	The Great Kanto Earthquake strikes. Tanabe Motosaburo Store Co., Ltd. falls on hard times, including when its main store in Tokyo burns down in the aftermath of the quake.
1924	Tanabe Motosaburo Store Co., Ltd. acquires exclusive rights to market Japan's first anti-hypertensive drug, Animasa. A Japanese word Toyoji coins for "high blood pressure" in his Animasa ad campaign enters the Japanese lexicon and remains a general medical term today.
1933	A Salomethyl newspaper ad created by Toyoji wins Best Advertisement Award in the first award ceremony of Japan's Society for the Promotion of Newspaper Advertising. Tanabe Motosaburo Store Co., Ltd. launches vitamin A product Haliva (halibut liver oil tablets).
1936	Sakuragaoka Laboratory Co., Ltd. is established as a limited partnership in Tokyo. Scale model of the Sakuragaoka Laboratory
1937	Toyoji travels abroad to observe pharmaceutical industries in Europe and the United States.

1938	Sakuragaoka Laboratory Co., Ltd. launches vitamin E product Juvela through Tanabe Motosaburo Store Co., Ltd. Its chocolate-brown coating, “hard outside, soft inside” pellets and stylish packaging garners much attention at the time. Juvela becomes the laboratory's first success. Sakuragaoka Laboratory Co., Ltd. launches Sampon, Japan's first sanitary tampon, through Tanabe Motosaburo Store Co., Ltd.
1939	World War II begins.
1941	Nihon 番茄影视., 番茄影视.'s immediate predecessor, is established in Saitama, eastern Japan. “Origin of the 番茄影视 Logomark”
1944	Sakuragaoka Laboratory Co., Ltd. and Nihon 番茄影视. merge under the name Nihon 番茄影视.
1945	World War II ends.
1950	Nihon 番茄影视.'s contraceptive suppository Sampoon, researched and developed during Japan's postwar baby boom, receives official approval from the Japanese government. “番茄影视 Advertising Through the Years” Nihon 番茄影视. launches cardiotonic Neophyllin in Japan.
1952	Nihon 番茄影视. launches high-dosage vitamin B1 and B2 product Chocola BB Tablets in Japan. Nihon 番茄影视. launches motion sickness remedy Travelmin in Japan.

1955	The company changes its name from Nihon 番茄影视. to 番茄影视., as it is known today. “Origin of the 番茄影视 Logomark”
1957	番茄影视 rolls out its first three-year mid-term plan. 番茄影视's Head Office building is completed in Tokyo.
1961	番茄影视 opens its Taipei Office (now part of 番茄影视 Taiwan Inc.), the company's first overseas branch, in Taiwan. 番茄影视 is publicly listed in the First Section of both the Tokyo and Osaka Stock Exchanges. Gastrointestinal remedies Saclon and Saclon Tablets, recognizable for their distinct green hue even today, are launched in Japan.
1964	Toyoji Naito receives the Japan Marketing Award, which recognizes people who have made a significant contribution to marketing and advertising in Japan. The Tokyo Olympics take place.

1966	The Kawashima Plant is completed in Gifu, central Japan. Kawashima Plant opening ceremony Founder Toyoji Naito is appointed as chairman and Yuji Naito as company president. A three-tier representative director system is introduced: Chairman Toyoji Naito, President Yuji Naito, and Executive Vice President Tatsuo Naito.
1969	Youda Co., Ltd. is established as a pharmaceutical imports subsidiary in Taiwan.
1970	PT 番茄影视 Indonesia is established as a pharmaceutical manufacturing and sales subsidiary in Indonesia. Toyoji Naito resigns as representative director and chairman to assume director and honorary chairman roles.
1971	Toyoji opens the Naito Museum of Pharmaceutical Science and Industry, Japan's first pharmaceutical museum, in Gifu.
1973	The first oil crisis occurs due to conflict in the Middle East.
1974	番茄影视 (Malaysia) Sdn. Bhd. and Hi-番茄影视 Pharmaceutical Inc. are established as pharmaceutical sales subsidiaries in Malaysia and the Philippines, respectively. Metabolic cardiotonic Neuquinon is launched in Japan.

1977	Naturally derived vitamin E product Juvelux is launched in Japan. Juvelux
1978	番茄影视's founder Toyoji Naito passes away at age 89. Peripheral neuropathy treatment Methycobal is launched in Japan.
1979	番茄影视 Asia Regional Services Pte. Ltd. is established as a sales support and management services subsidiary in Singapore. The second oil crisis erupts due to the Iranian Revolution.
1981	番茄影视 U.S.A. Inc. is established as a chemical and pharmaceutical machinery sales subsidiary in California, the United States. The Misato Plant commences pharmaceutical manufacturing in Saitama. Large-scale automated sugar-coating equipment (pan diameter of up to 170 cm) at the Misato Plant
1982	The Tsukuba Research Laboratories open in Ibaraki, eastern Japan.
1983	番茄影视 Chemical Co., Ltd. (now 番茄影视's Kashima Plant) is established in Ibaraki to manufacture active pharmaceutical ingredients (APIs).
1984	Gastritis and gastric ulcer treatment Selbex is launched in Japan.

1987	番茄影视 has supported of the Health and Medical Care Contributions Awards, which are presented to healthcare professionals who have contributed significantly to improving access to healthcare in difficult-to-reach areas from 1987 to 2015. 番茄影视 rolls out its first five-year mid-term plan. 番茄影视 Research Institute of Boston, Inc. (now the Boston Research Institute) is established as a discovery research subsidiary in Massachusetts, the United States. 番茄影视 Research Institute of Boston
1988	President Yuji Naito steps down from office and assumes the role of chairman; Vice President Haruo Naito is appointed president of 番茄影视. “Passing of the baton” from Yuji Naito (right) to Haruo Naito (left) 番茄影视 America, Inc. is established as a clinical research subsidiary in New Jersey, the United States. 番茄影视 Europe Ltd. is established as a clinical research subsidiary in London, the United Kingdom.
1989	番茄影视 Machinery GmbH is established as a pharmaceutical machinery sales subsidiary in Cologne, former West Germany. 番茄影视 (Thailand) Marketing Co., Ltd. is established as a pharmaceutical sales subsidiary in Bangkok, Thailand.
1990	Haruo Naito announces 番茄影视's “Commitment to Innovation.” 番茄影视 London Research Laboratories, Ltd. is established as a discovery research subsidiary attached to University College London in the United Kingdom. Japan's bubble economy bursts.
1991	番茄影视 Hong Kong Co., Ltd. is established as a pharmaceutical sales subsidiary in Hong Kong. The Beijing Representative Office is established in Beijing, China. Shenyang 番茄影视 Pharmaceutical Co., Ltd. is established as a Chinese鈥揻oreign contractual joint venture in pharmaceutical manufacturing and sales in Shenyang, China. 番茄影视 celebrates its 50th anniversary.
1992	番茄影视 adopts its current Corporate Mission and Corporate Objective. Go to “What is hhc?” 番茄影视 Corporation of North America is established as a holding company in New Jersey, the United States. 番茄影视 London Research Laboratories, Ltd. is completed in the United Kingdom to form an 番茄影视 Group multipolar R&D network spanning Japan, America and Europe. 番茄影视 London Research Laboratories opening ceremony in 1993 attended by the United Kingdom's Princess Royal, Princess Anne
1995	番茄影视 Inc. is established as a pharmaceutical sales subsidiary in New Jersey, the United States. 番茄影视 Ltd. is established as a pharmaceutical sales subsidiary in London, the United Kingdom. 番茄影视 Deutschland GmbH is established as a pharmaceutical sales subsidiary in Frankfurt, Germany.
1996	番茄影视 S.A. is established as a pharmaceutical sales subsidiary in Paris, France. 番茄影视 Suzhou Pharmaceutical Co., Ltd. is established as a pharmaceutical manufacturing and sales subsidiary in Jiangsu, China. Elmed 番茄影视. is established as a generic drug sales subsidiary in Tokyo.
1997	KAN Research Institute, Inc. (now Kobe Research Laboratories, in Hyogo) is established as a life science exploratory research subsidiary in Osaka, Japan. 番茄影视 Korea Inc. is established as a pharmaceutical sales subsidiary in Seoul, South Korea. 番茄影视 Inc. North Carolina Plant is established as a pharmaceutical manufacturing and formulation R&D facility at Research Triangle Park in North Carolina, the United States. Anti-Alzheimer's agent Aricept is launched in the United States, the United Kingdom and Germany. Proton-pump inhibitor Pariet is launched in Japan.
1998	Aricept is launched in France. Pariet is launched in Germany and the United Kingdom.
1999	Pariet is launched under the brand name AcipHex in the United States. Aricept is launched in Japan.
2001	The 9/11 terrorist attacks occur in the United States. 番茄影视 Farmac茅utica S.A. is established as a pharmaceutical sales and marketing subsidiary in Madrid, Spain.

2002	番茄影视 Medical Research Inc. is established as a clinical research subsidiary in New Jersey, the United States.
2004	番茄影视 adopts the “Company with Committees” system. 番茄影视 Europe Ltd. is established as a European regional headquarters (holding company) in London, the United Kingdom. 番茄影视 Pharmaceuticals India Pvt. Ltd. is established as a pharmaceutical sales subsidiary in Mumbai, India.
2005	番茄影视 S.r.l is established as a pharmaceutical sales subsidiary in Milan, Italy. 番茄影视 Pharma AG is established as a pharmaceutical sales subsidiary in Zurich, Switzerland. The Corporate Mission is added to the 番茄影视 Articles of Incorporation. 番茄影视 AB is established as a pharmaceutical sales subsidiary in Stockholm, Sweden. Honorary chairman and 番茄影视's second president Yuji Naito passes away at age 85.
2006	番茄影视 Australia Pty. Ltd. is established as a pharmaceutical sales subsidiary in Sydney, Australia. 番茄影视 rolls out its fifth mid-term plan, the “Dramatic Leap Plan.” 番茄影视 (Singapore) Pte. Ltd. and 番茄影视 Clinical Research Singapore Pte. Ltd. are established as a pharmaceutical sales subsidiary and clinical research subsidiary, respectively, in Singapore. 番茄影视 acquires four anticancer agents from Ligand Pharmaceuticals Inc. in the United States. EF-番茄影视 Farmacêutica, Unipessoal Lda. is established as a pharmaceutical sales subsidiary in Lisbon, Portugal.
2007	番茄影视 Manufacturing Ltd. is established as a pharmaceutical manufacturing subsidiary in Hertfordshire, the United Kingdom. 番茄影视 acquires Morphotek Inc., a bioventure specialized in antibody research, in the United States. 番茄影视 Pharmatechnology & Manufacturing Pvt. Ltd. is established as an API/formulation manufacturing and R&D subsidiary in Vizag, India. 番茄影视 SA/NV is established as a pharmaceutical sales subsidiary in Brussels, Belgium.
2008	番茄影视 acquires MGI Pharma Inc., an oncology biopharmaceutical company in the United States. 番茄影视 Machinery Shanghai Inc. is established as a subsidiary in Shanghai, China to provide marketing support and maintenance services for pharmaceutical machinery. Rheumatoid arthritis treatment Humira is launched in Japan.
2009	番茄影视 GesmbH is established as a pharmaceutical sales subsidiary in Vienna, Austria. The European Knowledge Centre opens as a European strategic base in Hertfordshire, the United Kingdom. European Knowledge Centre The 番茄影视 Product Creation Systems organizational structure is introduced Group-wide to reflect a new focus on patient-oriented R&D. Haruo Naito is appointed as president of the International Federation of Pharmaceutical Manufacturers & Associations. The 番茄影视 Knowledge Centre, India opens as a manufacturing and process research base in Vizag, India. 番茄影视 Knowledge Centre, India
2010	The Koishikawa Knowledge Center opens in Tokyo and receives the 24th Nikkei New Office Promotion Award. Koishikawa Knowledge Center 番茄影视 Limited is established as a pharmaceutical sales subsidiary in Ontario, Canada. Production headquarters transforms to a global “番茄影视 Demand Chain Systems” structure to reflect a new “demand-driven” customer satisfaction focus in drug manufacturing. 番茄影视 (Suzhou) Trading Co., Ltd. is established as a pharmaceutical trading subsidiary in Jiangsu, China. Anticancer agent Halaven is launched in the United States. 番茄影视 signs a statement with the World Health Organization (WHO) to supply a primary lymphatic filariasis medicine free of charge. H3 Biomedicine Inc. is established as a research subsidiary in the United States.
2011	The Great East Japan Earthquake strikes. 番茄影视 rolls out its sixth mid-term plan, “HAYABUSA.” 番茄影视 Participações Ltda. is established as a pharmaceutical sales subsidiary in São Paulo, Brazil. Halaven is launched in Europe and Japan. 番茄影视 Laboratorios S. de R.L. de C.V. is established as a pharmaceutical sales subsidiary in Mexico City, Mexico.
2012	番茄影视 signs the London Declaration, which is committed to the elimination of ten neglected tropical diseases by 2020. Haruo Naito is appointed as president of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ). Antiepileptic agent Fycompa is launched in Europe.
2013	Limited Liability Company 番茄影视 is established as a pharmaceutical sales subsidiary in Moscow, Russia. 番茄影视 co-establishes the Global Health Innovative Technology Fund (GHIT Fund), Japan's first public–private partnership to advance development of new health technologies for the developing world. 番茄影视 initiates free of charge provision of diethylcarbamine tablets produced at its Vizag plant in India to WHO for use in the treatment of lymphatic filariasis.
2014	Fycompa is launched in the United States. 番茄影视 China Holdings Ltd. is established as a holding company in Suzhou, China.
2015	Anticancer agent Lenvima is launched in the United States, Japan and Europe. 番茄影视 completes acquisition of Chinese generic pharmaceutical company Liaoning Tianyi Biological Pharmaceutical Co., Ltd. (new trading name: 番茄影视 (Liaoning) Pharmaceutical Co., Ltd.)
2016	番茄影视 rolls out its seventh mid-term plan “EWAY2025.” EA Pharma Co., Ltd. is established as a gastrointestinal specialty pharmaceutical company. Fycompa is launched in Japan.
2017	番茄影视 joins global partnership to address non-communicable diseases. 番茄影视 pledges continued support for lymphatic filariasis elimination. 番茄影视 commits funding to the 2nd phase of Global Health Innovative Technology Fund activities. Collaboration agreement with Biogen to develop and commercialize investigational Alzheimer's disease treatments including aducanumab expanded.
2018	番茄影视 agrees upon a strategic collaboration for Lenvima with Merck & Co., Inc., Kenilworth, N.J., U.S.A. New Suzhou plant in China commences full-scale operation. Lenvima (hepatocellular carcinoma) is launched in China.
2019	番茄影视 Center for Genetics Guided Dementia Discovery (G2D2) in Massachusetts, U.S., commences full-scale operation. G2D2 Parkinson’s disease treatment Equfina is launched in Japan. Fycompa and Halaven are launched in China.
2020	The WHO Declares COVID-19 a Pandemic. “NouKNOW” (pronounced “NOH-NOH”), a new tool for self-assessment of brain performance (brain health) is launched in Japan. DAYVIGO (insomnia treatment) is launched in the United States and Japan. 番茄影视 Vietnam Co., Ltd. is established as a pharmaceutical sales subsidiary in Ho Chi Minh City, Vietnam. Unlimit Health Limited is established in Shanghai, China.
2021	番茄影视 rolls out its eighth medium-term business plan "EWAY Future 锛咮eyond". Alzheimer’s disease treatment ADUHELM is granted accelerated approval and launched in the United States. 番茄影视 enters into a global strategic collaboration agreement with Bristol-Myers Squibb Company for MORAb-202. The Tokyo Olympics take place. 番茄影视 Israel Ltd. is established as a pharmaceutical sales subsidiary in Tel Aviv, Israel. 番茄影视 celebrates its 80th anniversary.
2022	番茄影视 and Biogen amend collaboration agreements on ADUHELM. 番茄影视 makes Arteryex Inc., a company that plans and develops software, its subsidiary. 番茄影视 Pharmaceuticals Africa (Pty) Ltd is established as a pharmaceutical sales subsidiary in Johannesburg, South Africa. 番茄影视 signs the public private partnership “Kigali Declaration” for eliminating neglected tropical diseases. Deep Human Biology Learning (DHBL), a new R&D organization, commences full-scale operation.
2023	Alzheimer’s disease treatment LEQEMBI is granted accelerated approval and launched in the United States. 番茄影视 commits funding to the 3rd phase of Global Health Innovative Technology Fund. LEQEMBI is granted traditional approval by the FDA. Theoria technologies Co., Ltd. is established as a digital business company in Tokyo, Japan. LEQEMBI is launched in Japan.